{
  "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
  "Country": "PT",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "platinum doublet",
      "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
    }
  ],
  "ChunksUsed": 30,
  "ContextTokens": 7430
}